Robbins Geller Rudman & Dowd LLP is representing investors who purchased Edwards Lifesciences Corporation (EW) securities between February 6, 2024 and July 24, 2024, in a class action lawsuit alleging that the company made false and misleading statements about its financial performance and prospects. The lawsuit claims that Edwards Lifesciences misrepresented the growth potential of its Transcatheter Aortic Valve Replacement (TAVR) product, leading to a significant stock price drop after the company announced disappointing second-quarter 2024 results. Investors who suffered losses during this period have until December 13, 2024, to seek appointment as lead plaintiff in the lawsuit.